|
1
|
Jemal A, Bray F, Center MM, et al: Global
cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
|
|
2
|
O'Driscoll L and Clynes M: Biomarkers and
multiple drug resistance in breast cancer. Curr Cancer Drug
Targets. 6:365–384. 2006. View Article : Google Scholar
|
|
3
|
Coley HM: Mechanisms and strategies to
overcome chemotherapy resistance in metastatic breast cancer.
Cancer Treat Rev. 34:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gonzalez-Angulo AM, Morales-Vasquez F and
Hortobagyi GN: Overview of resistance to systemic therapy in
patients with breast cancer. Adv Exp Med Biol. 608:1–22. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Marquette C and Nabell L:
Chemotherapy-resistant metastatic breast cancer. Curr Treat Options
Oncol. 13:263–275. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lai EC: MicroRNAs are complementary to
3′UTR sequence motifs that mediate negative post-transcriptional
regulation. Nat Genet. 30:363–364. 2002.
|
|
7
|
Guo H, Ingolia NT, Weissman JS and Bartel
DP: Mammalian microRNAs predominantly act to decrease target mRNA
levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sempere LF, Christensen M, Silahtaroglu A,
et al: Altered MicroRNA expression confined to specific epithelial
cell subpopulations in breast cancer. Cancer Res. 67:11612–11620.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Majumder S and Jacob ST: Emerging role of
microRNAs in drug-resistant breast cancer. Gene Expr. 15:141–151.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kastl L, Brown I and Schofield AC:
miRNA-34a is associated with docetaxel resistance in human breast
cancer cells. Breast Cancer Res Treat. 131:445–454. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhu H, Wu H, Liu X, et al: Role of
MicroRNA miR-27a and miR-451 in the regulation of
MDR1/P-glycoprotein expression in human cancer cells. Biochem
Pharmacol. 76:582–588. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kovalchuk O, Filkowski J, Meservy J, et
al: Involvement of microRNA-451 in resistance of the MCF-7 breast
cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther.
7:2152–2159. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bao L, Hazari S, Mehra S, et al: Increased
expression of P-glycoprotein and doxorubicin chemoresistance of
metastatic breast cancer is regulated by miR-298. Am J Pathol.
180:2490–2503. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ng EK, Wong CL, Ma ES and Kwong A:
MicroRNAs as new players for diagnosis, prognosis, and therapeutic
targets in breast cancer. J Oncol. 2009:3054202009.PubMed/NCBI
|
|
15
|
Iorio MV, Casalini P, Tagliabue E, et al:
MicroRNA profiling as a tool to understand prognosis, therapy
response and resistance in breast cancer. Eur J Cancer.
44:2753–2759. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang QQ, Xu H, Huang MB, et al:
MicroRNA-195 plays a tumor-suppressor role in human glioblastoma
cells by targeting signaling pathways involved in cellular
proliferation and invasion. Neuro Oncol. 14:278–287. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fei X, Qi M, Wu B, et al: MicroRNA-195-5p
suppresses glucose uptake and proliferation of human bladder cancer
T24 cells by regulating GLUT3 expression. FEBS Lett. 586:392–397.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
McCubrey JA, Steelman LS, Chappell WH, et
al: Roles of the Raf/MEK/ERK pathway in cell growth, malignant
transformation and drug resistance. Biochim Biophys Acta.
1773:1263–1284. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cekanova M, Majidy M, Masi T, et al:
Overexpressed Raf-1 and phosphorylated cyclic adenosine
3′-5′-monophosphatate response element-binding protein are early
markers for lung adenocarcinoma. Cancer. 109:1164–1173.
2007.PubMed/NCBI
|
|
20
|
Hoyle PE, Moye PW, Steelman LS, et al:
Differential abilities of the Raf family of protein kinases to
abrogate cytokine dependency and prevent apoptosis in murine
hematopoietic cells by a MEK1-dependent mechanism. Leukemia.
14:642–656. 2000. View Article : Google Scholar
|
|
21
|
Chang F, Steelman LS and McCubrey JA:
Raf-induced cell cycle progression in Human TF-1hematopoietic
cells. Cell Cycle. 1:220–226. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hwang YH, Choi JY, Kim S, et al:
Overexpression of c-raf-1 proto-oncogene in liver cirrhosis and
hepatocellular carcinoma. Hepatol Res. 29:113–121. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Steelman LS, Chappell WH, Abrams SL, et
al: Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in
controlling growth and sensitivity to therapy-implications for
cancer and aging. Aging. 3:192–222. 2011.PubMed/NCBI
|
|
24
|
Meslin F, Hamaï A, Gao P, et al: Silencing
of prion protein sensitizes breast adriamycin-resistant carcinoma
cells to TRAIL-mediated cell death. Cancer Res. 67:10910–10919.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lu C, Shao C, Cobos E, et al:
Chemotherapeutic sensitization of leptomycin B resistant lung
cancer cells by pretreatment with doxorubicin. PLoS One.
7:e328952012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Blenkiron C, Goldstein LD, Thorne NP,
Spiteri I, et al: MicroRNA expression profiling of human breast
cancer identifies new markers of tumor subtype. Genome Biol.
8:R2142007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hannafon BN, Sebastiani P, de las Morenas
A, et al: Expression of microRNA and their gene targets are
dysregulated in preinvasive breast cancer. Breast Cancer Res.
13:R242011. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Waters PS, McDermott AM, Wall D, et al:
Relationship between circulating and tissue microRNAs in a murine
model of breast cancer. PLoS One. 7:e504592012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu L, Chen L, Xu Y, et al: microRNA-195
promotes apoptosis and suppresses tumorigenicity of human
colorectal cancer cells. Biochem Biophys Res Commun. 400:236–240.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu T, Zhu Y, Xiong Y, et al: MicroRNA-195
suppresses tumorigenicity and regulates G1/S transition of human
hepatocellular carcinoma cells. Hepatology. 50:113–121. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dai Y, Xie CH, Neis JP, et al: MicroRNA
expression profiles of head and neck squamous cell carcinoma with
docetaxel-induced multidrug resistance. Head Neck. 33:786–791.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang X, Yin J, Yu J, et al: miRNA-195
sensitizes human hepatocellular carcinoma cells to 5-FU by
targeting BCL-w. Oncol Rep. 27:250–257. 2012.PubMed/NCBI
|
|
34
|
Flavin RJ, Smyth PC, Laios A, et al:
Potentially important microRNA cluster on chromosome 17p13.1 in
primary peritoneal carcinoma. Mod Pathol. 22:197–205. 2009.
View Article : Google Scholar
|
|
35
|
Subramanian RR and Yamakawa A: Combination
therapy targeting Raf-1 and MEK causes apoptosis of HCT116 colon
cancer cells. Int J Oncol. 41:1855–1862. 2012.PubMed/NCBI
|
|
36
|
Monazzam A, Razifar P, Ide S, et al:
Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular
tumour spheroids with respect to effects on growth and PET tracer
uptake. Nucl Med Biol. 36:335–342. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Leicht DT, Balan V, Kaplun A, et al: Raf
kinases: function, regulation and role in human cancer. Biochim
Biophys Acta. 1773:1196–1212. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li D, Zhao Y, Liu C, et al: Analysis of
MiR-195 and MiR-497 expression, regulation and role in breast
cancer. Clin Cancer Res. 17:1722–1730. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bandera CA, Muto MG, Welch WR, et al:
Genetic imbalance on chromosome 17 in papillary serous carcinoma of
the peritoneum. Oncogene. 16:3455–3459. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ghebeh H, Lehe C, Barhoush E, et al:
Doxorubicin downregulates cell surface B7-H1 expression and
upregulates its nuclear expression in breast cancer cells: role of
B7-H1 as an anti-apoptotic molecule. Breast Cancer Res. 12:R482010.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang X, Thomson SR, Starkey JD, et al:
Transforming growth factor beta1 is upregulated by activated Raf in
skeletal myoblasts but does not contribute to the
differentiation-defective phenotype. J Biol Chem. 279:2528–2534.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Leontovich AA, Zhang S, Quatraro C, et al:
Raf-1 oncogenic signaling is linked to activation of mesenchymal to
epithelial transition pathway in metastatic breast cancer cells.
Int J Oncol. 40:1858–1864. 2012.PubMed/NCBI
|
|
43
|
Weinstein-Oppenheimer CR, Henriquez-Roldan
CF, Davis JM, et al: Role of the Raf signal transduction cascade in
the in vitro resistance to the anticancer drug doxorubicin. Clin
Cancer Res. 7:2898–2907. 2001.PubMed/NCBI
|
|
44
|
Anderson LR, Sutherland RL and Butt AJ:
BAG-1 overexpression attenuates luminal apoptosis in MCF-10A
mammary epithelial cells through enhanced RAF-1 activation.
Oncogene. 29:527–538. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bodur C and Basaga H: Bcl-2 inhibitors:
emerging drugs in cancer therapy. Curr Med Chem. 19:1804–1820.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Shen Y, Chu Y, Yang Y and Wang Z:
Mitochondrial localization of P-glycoprotein in human breast cancer
cell line MCF-7/ADM and its functional characterization. Oncol Rep.
27:1535–1540. 2012.PubMed/NCBI
|
|
47
|
Gollob JA, Wilhelm S, Carter C and Kelley
SL: Role of Raf kinase in cancer: therapeutic potential of
targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol.
33:392–406. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Singh R and Saini N: Downregulation of
BCL2 by miRNAs augments drug-induced apoptosis - a combined
computational and experimental approach. J Cell Sci. 125:1568–1578.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Neelakandan K, Babu P and Nair S: Emerging
roles for modulation of microRNA signatures in cancer
chemoprevention. Curr Cancer Drug Targets. 12:716–740. 2012.
View Article : Google Scholar : PubMed/NCBI
|
